PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.09%
Both companies show declining cash positions (-9.09% vs TRAW's -15.09%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Cash + STI yoy 0.5-0.75x TRAW's -15.09%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-38.56%
Other current assets growth < half of TRAW's 14.77%. David Dodd sees a leaner approach to short-term items.
-10.41%
Similar yoy growth to TRAW's -11.29%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
-5.27%
Below half TRAW's 52.94%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.98%
Higher Long-Term Investments Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.72%
Below half of TRAW's 50.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Similar yoy to TRAW's -11.26%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
-5.64%
Less than half of TRAW's 21.24%. David Dodd sees a more disciplined AP approach or lower volume.
1.56%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Less than half of TRAW's -6.89%. David Dodd sees fewer expansions in other current obligations.
-5.23%
Less than half of TRAW's 11.63%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Less than half of TRAW's -1.96%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Less than half of TRAW's 8.22%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.21%
≥ 1.5x TRAW's -1.00%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.89%
0.75-0.9x TRAW's -23.18%. Bill Ackman wonders if competitor is growing equity faster.
-10.20%
Similar yoy to TRAW's -11.26%. Walter Schloss sees parallel expansions in total capital.
0.98%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-5.39%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
9.19%
50-75% of TRAW's 15.09%. Bruce Berkowitz notes comparatively lower net debt expansion.